Adjuvant chemoradiation may improve survival over adjuvant chemotherapy in resected pancreatic cancer patients who are high risk for locoregional recurrence
Tóm tắt
The objective of the study was to evaluate the benefit of adjuvant chemoradiation compared to adjuvant chemotherapy for resected pancreatic head cancer. Three hundred thirty-nine patients (2000–2012) had pancreatoduodenectomy for pancreatic cancer. Chemotherapy was gemcitabine or 5-fluorouracil (5-FU) and radiotherapy was 45–54 Gy. Locoregional recurrences (LRR) were operative bed or regional nodal failures. Logistical regression, Kaplan-Meier estimates, and log-rank tests were used for statistics. One hundred thirty patients had resection alone (A), 84 had adjuvant chemotherapy (B), and 129 had adjuvant chemoradiation (C). Median follow-up and median survival (MS) for all patients was 17.5 and 19.5 months, respectively. MS for groups A, B, and C were 13, 23, and 26 months, respectively. Groups B and C had R1 resection rates of 37 and 39 % (p = ns). LRR was 60, 63, and 38 % and distant failure was 64, 65, and 66 % for groups A, B, and C, respectively. Group C had significantly lower LRR compared to group B (p = 0.01); however, survival between groups B and C was not statistically different (p = 0.23). On univariate analysis, LRR (p = 0.0038), N-category (p < 0.0001), perineural invasion (PNI; p = 0.007), and R1 resection (p = 0.018) were significant predictors of survival. Multivariable analysis (MVA) showed that LRR (p = 0.004) and N-category (p = 0.01) were predictors of survival. On subgroup analysis, there was improved survival in group C vs B in patients with R1 resection, MS of 27 vs 16 months, respectively (p = 0.01), and in patients with lymph node ratio (LNR) ≤0.2 who had ≥8 LN dissected, MS of 32 vs 24 months (p = 0.04). Adjuvant chemoradiation significantly decreases LRR in resected pancreatic cancer patients compared to adjuvant chemotherapy. Significant predictors of survival on MVA were LRR and N-category. Additionally on subgroup analysis, chemoradiation improved survival over chemotherapy with a (1) positive surgical margin and/or (2) LNR ≤0.2 with ≥8 LNs dissected.
Tài liệu tham khảo
Hartwig W et al (2013) Improvement of surgical results for pancreatic cancer. Lancet Oncol 14:e476–e485. doi:10.1016/S1470-2045(1013)70172-70174
Hishinuma S et al (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10:511–518
Whittington R et al (1991) Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21:1137–1143
Corsini MM et al (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol 26:3511–3516
Stocken DD et al (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92:1372–1381
O’Reilly EM (2013) Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol 107:78–85
Hattangadi JA et al (2009) Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer 115:3640–3650
Winter JM et al (2013) Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to smad4 expression. Ann Surg 258:331–335
Moghanaki D et al (2011) Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. JOP 12:438–444
Kim R et al (2010) A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg 14:1159–1169
Herman JM et al (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26:3503–3510. doi:10.1200/JCO.2007.3515.8469
Butturini G et al (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg (Chicago, Ill: 1960) 143:75–83, discussion 83
Kooby DA et al (2013) Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Annals Surg Oncol
Gnerlich JL et al (2012) Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg (Chicago, Ill: 1960) 147:753–760
Rau BM et al (2012) R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery 152:S103–S111
Wentz SC et al (2012) Lymph node ratio and preoperative ca 19–9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol 4:207–215
Zhang Y et al (2012) Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol 138:1063–1071
Asiyanbola B et al (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13:752–759
Hall WA et al (2013) The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer 119:2350–2357
Konstantinidis IT et al (2013) Pancreatic ductal adenocarcinoma: is there a survival difference for r1 resections versus locally advanced unresectable tumors? What is a “true” r0 resection? Ann Surg 257:731–736
Pawlik TM et al (2007) Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141:610–618